Strong performance of overseas subsidiaries of companies

Beijing Hanmi records new sales

Beijing Hanmi's sales in the first half of the year increased by 173.3 billion won compared to the same period last year

Starting from the left, "Beijing Hanmi", "YANGZHOU ILYANG PHARM", "GC China"

Daewoong Pharmaceutical's Southeast Asian subsidiary doubled in a year.

 

Major overseas subsidiaries of pharmaceutical bio companies showed strong sales in the first half of last year.

 

Most of the local subsidiaries in China and Southeast Asia showed an increase in sales compared to the same period last year.

 

Beijing Hanmi, Celltrion AP (Asia-Pacific), and Celltrion USA set new sales records based on half-year sales.

 

◆ Beijing Hanmi records half-year sales According to the Financial Supervisory Service on the 20th, the combined sales of 22 Chinese local subsidiaries of 10 Korean pharmaceutical companies in the first half of the year were 314.8 billion won.

 

It increased 14% compared to 275.4 billion won during the same period last year.

 

Net profit increased 28% from 38.5 billion won in the first half of last year to 49.1 billion won in the first half of this year.

 

Beijing Hanmi broke the previous half-year sales record by making 173.3 billion won in sales in the first half of the year.

 

It increased 30% compared to 132.9 billion won in sales in the first half of last year.

 

Half-year sales of Beijing Hanmi recorded around 120 billion won before COVID-19.

 

In the first half of 2020, when COVID-19 was rampant in China, it plunged to 92.8 billion won.

 

However, after recovering to 110.7 billion won in the second half of 2020, 132.9 billion won in the first half of last year, 155.8 billion won in the second half of this year, and 173.3 billion won in the first half of this year.

 

Beijing Hanmi expanded its syrup factory last year.

 

The operation rate of this plant has been maintained at 100% this year.

 

An official from the U.S.

 

in Beijing explained, "As a result of timely expansion of facilities and supplying products in line with the rapid increase in demand for respiratory patients and cold medicines in China, we achieved solid performance until the first and second quarters." Most of the other Chinese subsidiaries have also grown by a large margin.

 

In the case of Chong Kun Dang, sales at Chong Kun Dang Health in Qingdao more than tripled from 1.1 billion won to 6.7 billion won.

 

Guangdong Pharmaceutical's total sales in the first half of the year were 20.1 billion won, up 24% from the same period last year.

 

Daewoong Pharmaceutical has four subsidiaries in China, including Sacheon Daewoong Biotechnology Limited, Liaoning Daewoong Pharmaceutical Limited, and Beijing Daewoong Pharmaceutical and Technology Limited.

 

The combined sales of the four corporations increased 39% from 8.8 billion won to 12.3 billion won in a year.

 

YANGZHOU ILYANG PHARM·TONGHUA ILYANG HEALTH PRODUCTS of Ilyang Pharmaceutical recorded 71.2 billion won in sales in the first half of the year.

 

It increased by 5% compared to 67.7 billion won in the first half of last year.

 

Among major Chinese subsidiaries, sales of GC Pharma's subsidiaries declined.

 

Total sales of GC China and GC China Pharm fell 34% year-on-year to 29.8 billion won.

 

◆ Celltrion and Takeda products in earnest in the Asia-Pacific region, Diagnostic kits are booming in the U.S Local subsidiaries in Southeast Asia also performed well in the first half of the year.

 

Particularly noticeable is Celltrion's Celltrion Asia Pacific PTE located in Singapore.

 

It recorded 75 billion won in sales in the first half of this year.

 

It nearly tripled from 25.2 billion won in the first half of last year.

 

Net profit also shifted from a deficit of 6.8 billion won to a surplus of 9.7 billion won.

 

Analysts say that the sale of 18 products acquired from Takeda Pharmaceutical has begun in earnest.

 

Celltrion Pharmaceutical is in charge of sales in Korea, and Celltrion Asia Pacific PTE is in charge of sales in the remaining eight countries, including Thailand, Taiwan, Hong Kong, Macau, the Philippines, Singapore, Malaysia, and Australia.

 

In the case of Daewoong Pharmaceutical, the total sales of five local subsidiaries located in Thailand, Indonesia, and the Philippines more than doubled from 8.4 billion won to 17.2 billion won.

 

In the case of Chong Kun Dang, sales of local subsidiaries in Indonesia increased 2.2 times from 2.1 billion won to 4.7 billion won in a year.

 

In addition, in the North American market, Celltrion USA made strides by increasing its sales nearly 16 times in a year.

 

Celltrion USA's sales in the first half of this year increased from 9.4 billion won last year to 150.4 billion won in the first half of this year.

 

Celltrion USA's sales expansion is attributed to strong sales of COVID-19 diagnostic kits.

 

Celltrion is jointly developing and selling antibody diagnostic kits, antigen rapid diagnostic kits, antigen home test diagnostic kits, and neutralization antibody diagnostic kits with Humasis.

 

Among them, antigen rapid diagnostic kits and antigen home test diagnostic kits have been supplied to the U.S.

 

in earnest since late last year through Celltrion USA.